Drug intelligence / Profile preview

XAB05

Development stage: Phase 1
Lead developer: Xenothera
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**XAB05** is a glyco-humanized polyclonal antibody developed for the prevention and treatment of multi-drug resistant bacterial infections. It is designed as an *immunostimulant*, leveraging Xenothera's proprietary technology that modifies glycosylation patterns to reduce immunogenicity and enhance safety. The drug acts by stimulating the immune response against bacterial pathogens and is primarily targeted for infectious diseases, where antibiotic resistance presents a significant clinical challenge. Its development highlights a focus on innovative antibody-based therapies for conditions not adequately addressed by conventional treatments.

Brand names: XAB05XAB-05XAB 05
Other names: XAB05XAB-05XAB 05

Targets

GPSM1 (Activator of G-protein signaling 8)

Beyond the preview

Go deeper on XAB05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XAB05.

Explore the full profile